AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OMER · NASDAQ · Biotechnology

Omeros

Commercializes YARTEMLEA for TA-TMA while advancing complement and specialty therapeutics.

$18.51

After-hours close−0.08 (−0.43%)

At close$18.59(−3.43%)

Something off on this page? Send us feedback.

Profile

Omeros CorporationOMERHealth Care

Markets YARTEMLEA in the U.S. for transplant-associated thrombotic microangiopathy and runs a one-segment biotech pipeline around complement, oncology, addiction, and infectious-disease programs. Former OMIDRIA royalties and Novo Nordisk's zaltenibart rights shape the post-divestiture economics.

Commercializes YARTEMLEA in the U.S. for transplant-associated thrombotic microangiopathy, using a field organization focused on transplant centers. The same one-segment platform covers MASP-2 and MASP-3 complement biology, OMS1029, OMS527, OncotoX-AML, and T-CAT.

Former OMIDRIA economics remain part of the business through royalty rights after the Rayner sale, while zaltenibart moved to Novo Nordisk under a global development and commercialization arrangement. The company remains founder-led from Seattle.

Execution depends on U.S. transplant-center adoption, payer access, and external manufacturers for YARTEMLEA supply. European access depends on CHMP re-examination after a negative opinion on the narsoplimab marketing application.

Company facts

CEOGregory A. Demopulos, M.D.

ListedOct 8, 2009

ExchangeNASDAQ

HeadquartersSeattle, WA

CountryUnited States

Employees175

CIK0001285819

ISINUS6821431029

Key statistics

Market cap$1.35B

EPS (ttm)$1.72

P/E (ttm)10.82

ROE-109.4%

P/B−26.14

P/S35.06

Dividend yield—

Beta1.75vs XLV −0.24

Year to date +13.5% · Average volume (30d) 2.1M

Analysts

Price target, next 12 months$33.00+77.3%Median of 19 analysts · vs the Aug 28 close

ConsensusBuy11 of 19 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $18.61

High$33.00+77.3%

Median$33.00+77.3%

Low$33.00+77.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior target	Target
Jun 29, 2026	H.C. Wainwright	Target	$40	$33
Jan 8, 2026	H.C. Wainwright	Target	$20	$40
Oct 15, 2025	H.C. Wainwright	Target	$9	$20

Earnings

EPS

Estimate−$0.05

ReportedDue Nov 12, 2026

Revenue

Estimate$36.7M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	−$0.27	$0.15	+155.9%	$12.7M	$28.5M	+124.8%	+26.55%
May 13, 2026Q1 FY26	−$0.40	−$0.24	+40.0%	$4.2M	$9.9M	+136.4%	−7.65%
Mar 31, 2026Q4 FY25	−$0.55	$3.14	+670.9%	$1.6M	—	—	+14.39%
Nov 13, 2025Q3 FY25	−$0.58	−$0.19	+67.2%	—	—	—	+25.32%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$9.9M	$28.5M
Gross profit	$0	−$10.3M	$0	$0	$9.1M	$27.7M
Operating income	−$35.0M	−$32.4M	−$26.4M	−$29.1M	−$17.4M	$74.0K
Net income	−$33.5M	−$25.4M	−$30.9M	$86.5M	$56.1M	$13.2M
Diluted EPS	−$0.58	−$0.43	−$0.47	$1.42	$0.62	$0.15
Gross margin	—	—	—	—	91.7%	97.2%
Operating margin	—	—	—	—	-176.1%	0.3%

Fiscal years (4-quarter sums)FY21 −$79.9M · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $132.0M · Total debt $83.8M · Total assets $286.8M · Shareholders' equity −$51.3M

Dividends

No dividends on record.

Ownership

Institutions 51.55%37.31M sharesInsiders 3.22%2.33M sharesOther 45.23%32.73M shares

Shares outstanding 72.38M · Float 69.80M · 96.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	6.04M	8.35%	13F	Aug 7, 2026
Ingalls & Snyder LLC	3.66M	5.06%	13F	Aug 14, 2026
UBS Group AG	3.15M	4.35%	13F	Aug 13, 2026
Vanguard Capital Management LLC	3.07M	4.24%	13F	Aug 13, 2026
State Street Corp	2.32M	3.21%	13F	Aug 7, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 27, 2026	Arnold C. Hanish	director	−10,000	$18.95
Aug 26, 2026	Arnold C. Hanish	director	−5,000	$18.53
Aug 24, 2026	David J. Borges	officer: VP, Finance & CAO	−906	$19.10
Aug 21, 2026	David J. Borges	officer: VP, Finance & CAO	−10,000	$18.95
Aug 20, 2026	Thomas J. Cable	director	−15,000	$18.45